

REMARKS

Claims 11, 12, 13, 16, 17, 18, 39, 61, 62, 64, 65, 66, and 67 will be pending.

There were two restriction requirements in this case. In the first restriction requirement of March 16, 2000, the above referenced claims were considered to be a separate group, i.e., Group III.

On January 4, 2001, without explanation or reference to the prior restriction requirement or applicants' election, a new Examiner issued a different restriction requirement. No explanation for this was given.

Applicants adhere to the first restriction requirement and elect claims 11-13, 16-18, 39, 61, 62, and 64-67 for examination.

Respectfully submitted,

By   
Norman D. Hanson  
Registration No.: 30,946  
FULBRIGHT & JAWORSKI L.L.P.  
666 Fifth Avenue  
New York, New York 10103  
(212) 318-3000  
(212) 318-3400 (Fax)  
Attorney for Applicant

~~ISOLATED PEPTIDES CORRESPONDING TO AMINO ACID  
REQUIREMENTS OF NY-ESO-1, WHICH BIND TO MHC CLASS I AND MHC  
CLASS II MOLECULES, AND USES THEREOF~~

ISOLATED NUCLEIC ACID MOLECULES WHICH  
ENCODE PEPTIDES WHICH BIND TO MHC CLASS  
II MOLECULES, SUCH AS HLA-DR53

## REPLACEMENT PAGE 1, LINES 1-7 OF SPECIFICATION

### RELATED APPLICATION

~~This application is a continuation in part of Serial No. 08/937,263, filed September 15, 1997, which is a continuation in part of Serial No. 08/725,182, filed October 3, 1996 now U.S. Patent No. \_\_\_\_\_. Both of these applications are incorporated by reference.~~

This application is a divisional of Serial Number 09/165,546, filed on October 2, 1998, which is a continuation-in-part of Serial Number 09/062,422, filed on April 17, 1998, now U.S. Patent Number 6,252,052, which is a continuation-in-part of Serial Number 08/937,263, filed on September 15, 1997, now U.S. Patent Number 6,274,145, which is a continuation-in-part of Serial Number 08/725,182, filed on October 3, 1996, now U.S. Patent No. 5,804,381. All patents are incorporated by reference.

**REPLACEMENT PAGE 6, LINES 4-5 OF SPECIFICATION**

~~Figure 3 shows potential sites for modification of the deduced amino acid sequence of NY-ESO-1.~~

Figure 3 shows potential sites for modification of the deduced amino acid sequence of NY-ESO-1 (the amino acid sequence is encoded by the nucleotide sequence of SEQ ID NO: 1, and is set forth therein).

**REPLACEMENT PAGE 28, LINES 2-4 AND LINES 5-10 OF SPECIFICATION**

~~Further studies were characterized to determine if CD4<sup>+</sup> helper T cells recognized complexes of MHC Class II molecules and peptides.~~

~~Tumor cell line MZ-MEL-19 has been types as being HLA-DR53 positive. Hence, NY-ESO-1 was screened using Futaki et al., *Immunogenetics*, 42:299-301 (1995), incorporated by reference, which teaches binding motifs for HLA-DR53. A total of twenty-eight peptides which, in theory, would bind to HLA-DR53, and antigens presenting cells alone.~~

Further studies were carried out to determine if CD4<sup>+</sup> helper T cells recognized complexes of MHC Class II molecules and peptides.

Tumor cell line MZ-MEL-19 has been types as being HLA-DR53 positive. Hence, NY-ESO-1 was screened using Futaki, et al., *Immunogenetics*, 42:299-301 (1995), incorporated by reference, which teaches binding motifs for HLA-DR53. A total of twenty-eight peptides which, in theory, would bind to HLA-DR53 were found.